PMV Pharmaceuticals, Inc.PMVPEarnings & Financial Report
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies targeting mutations in the p53 tumor suppressor gene, one of the most frequently altered genes in human cancers. Its lead product candidates address unmet medical needs for patients with hard-to-treat solid and hematologic malignancies, serving global oncology patient segments.
Revenue
$2.3M
Gross Profit
N/A
Operating Profit
$-25.2M
Net Profit
$-23.0M
Gross Margin
N/A
Operating Margin
-1100.5%
Net Margin
-1005.7%
YoY Growth
-27.8%
EPS
$-0.45
PMV Pharmaceuticals, Inc. Q4 FY2024 Financial Summary
PMV Pharmaceuticals, Inc. reported revenue of $2.3M (down 27.8% YoY) for Q4 FY2024, with a net profit of $-23.0M (down 46.0% YoY) (-1005.7% margin).
Key Financial Metrics
| Total Revenue | $2.3M |
|---|---|
| Net Profit | $-23.0M |
| Gross Margin | N/A |
| Operating Margin | -1100.5% |
| Report Period | Q4 FY2024 |
PMV Pharmaceuticals, Inc. Annual Revenue by Year
PMV Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $6.3M |
| 2024 | $10.7M |
| 2023 | $11.2M |
| 2022 | $3.6M |
PMV Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
PMV Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.2M | -46.1% | $-18.0M | -1464.0% |
| Q3 FY2025 | $1.5M | -43.4% | $-21.1M | -1422.9% |
| Q2 FY2025 | $1.7M | -39.7% | $-21.2M | -1255.0% |
| Q1 FY2025 | $1.9M | -34.5% | $-17.4M | -901.1% |
| Q4 FY2024 | $2.3M | -27.8% | $-23.0M | -1005.7% |
| Q3 FY2024 | $2.6M | -12.4% | $-19.2M | -735.2% |
| Q2 FY2024 | $2.8M | +3.9% | $-1.2M | -43.3% |
| Q1 FY2024 | $3.0M | +27.0% | $-15.3M | -517.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.8M | $2.6M | $2.3M | $1.9M | $1.7M | $1.5M | $1.2M |
| YoY Growth | 27.0% | 3.9% | -12.4% | -27.8% | -34.5% | -39.7% | -43.4% | -46.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $236.9M | $237.5M | $223.5M | $191.3M | $170.6M | $152.9M | $133.8M | $116.6M |
| Liabilities | $24.2M | $23.2M | $25.6M | $15.2M | $10.5M | $12.3M | $12.8M | $11.8M |
| Equity | $212.7M | $214.3M | $197.9M | $176.1M | $160.1M | $140.6M | $121.0M | $104.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.2M | $-1.6M | $-16.8M | $-16.7M | $-18.3M | $-18.3M | $-19.8M | $-17.2M |